

Health Disparities in Hematologic Malignancies: From Genes to Outreach

Weill Cornell Medicine; Belfer Auditorium

June 6-7, 2025

Day 1 - Friday June 6, 2025

7:30 am	Registration and Breakfast:
8:00 am <ul style="list-style-type: none">8:05	Opening remarks TBD_ Patient Advocate (10 min presentation + 5 min questions)
8:20- 10:05 am <ul style="list-style-type: none">8:208:358:509:05	Session 1: The impact of germline variants and genomic abnormalities Irene Ghobrial, M.D. Dana Farber Cancer Institute, Boston, MA <i>SU2C MM Dream team (Online study GWAS)</i> Lyndon Mitnaul, Ph.D. Pharmaceuticals, Inc., Tarrytown, New York <i>Together 4 Change Genomics and Equity Initiative.</i> Maureen Murphy, Ph.D. Wistar Institute, Philadelphia, PA <i>Germline variants (p53, HSP) in AA patients</i> Discussion leader: Irene Ghobrial, M.D. Dana Farber Cancer Institute, Boston, MA (45 min call to action-discussion)
9:50 -10:15 am	Coffee Break
10:15-11:45 pm <ul style="list-style-type: none">10:1510:3010:4511:00	Session 2: Prognostic and therapeutic implications of the molecular landscape- Part A Aaron Viny, M.D. Columbia University, New York, NY <i>Hispanic patients with new molecular variant of leukemia.</i> Wendy Cozen, D.O. University of California, Irvine, CA <i>HL and MM in AA patients</i> Sandeep Dave, M.D. Duke University, Durham, NC <i>Genetic Origins of Adverse Outcomes in African Americans with Lymphoma</i> Discussion leader: Wendy Cozen, D.O. University of California, Irvine, CA (45 min call to action-discussion)
11:45 pm	Lunch
1:00-3:15 pm	Session 3: The impact of social determinants of health on outcomes

<ul style="list-style-type: none"> • 1:00 • 1:15 • 1:30 • 1:45 • 2:00 • 2:15 	<p>Helen Ma, M.D. UC Irvine; A Long Beach Healthcare System in Long Beach, CA <i>Military exposure in the natural history of lymphoma among veterans</i></p> <p>Alison Walker, M.D. Moffit Cancer Center, Tampa, FL <i>Disparities in AML survival for patients in medically underserved areas</i></p> <p>Theresa Keegan, Ph.D. University of California Davis School of Medicine, Sacramento, CA <i>Sociodemographic disparities in survivorship of Hodgkin's lymphoma patients</i></p> <p>Oreofe Odejide, M.D. Dana Farber Cancer Institute, Boston, MA <i>Health insurance and end-of-life care for people with hematologic malignancies</i></p> <p>Wellington Fernandes da Silva, M.D. Instituto do Cancer do Estado de São Paulo (ICESP), Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil <i>Management and outcomes of ALL in resource-constrained settings</i></p> <p>Discussion leader: Warren Fingrut, M.D. The University of Texas MD Anderson Cancer Center (45 min call to action-discussion)</p>
3:00 -3:30 pm	Coffee Break
3:30-5:00 pm	Session 4: Developing strategies to increase community representation in clinical enrollment
<ul style="list-style-type: none"> • 3:30 • 4:00 • 4:10 • 4:20 	<p>Elisa Weiss, PhD. Sr. Vice President of Education, Services & Health Research, The Leukemia & Lymphoma Society <i>Understanding communication & financial needs for diverse blood cancer patient populations and their participation in clinical trials</i></p> <p>Victor Gonzalez Lymphoma Research Foundation <i>Health Equity/ Spanish Language Navigation project</i></p> <p>Mark Fiala, PhD. Washington University School of Medicine, St. Louis, MO <i>Use of patient portals for clinical trial recruitment</i></p> <p>Nina Logan, M.D. Leukemia & Lymphoma Society</p> <p>Enrique Diaz, M.D. University of Texas Health Science Center, San Antonio, TX</p> <p>Discussion leader: Oscar Lahoud, M.D. New York University Langone Hospital, Brooklyn, NY (40 min call to action-discussion)</p>
5:00 -5:45	Patient Advocacy Session

	Discussion Leader: Luis Malpica, MD The University of Texas MD Anderson Cancer Center
5:45-7:45pm	Poster Session and Happy Hour

Day 2 - Saturday, June 7, 2025

8:00- 8:30 am	Registration and Breakfast
8:30- 8:30 am	<i>Session 5: Prognostic and therapeutic implications of the molecular landscape- Part B</i>
<ul style="list-style-type: none"> 8:30 	Rosalie Griffin Ph.D. Mayo Clinic, Rochester, MN <i>Genetic origins of lymphoma and CLL in minorities</i>
<ul style="list-style-type: none"> 8:45 	H. Leighton Grimes, Ph.D. Cincinnati Children's, Hospital, Cincinnati, OH <i>A genetic-genomics dissection of ancestry associated outcomes in acute myeloid leukemia.</i>
<ul style="list-style-type: none"> 9:00 	Lawrence Boise, Ph.D. Emory University School of Medicine, Atlanta, GA <i>Defining the landscape of structural alterations in African American Multiple Myeloma</i>
<ul style="list-style-type: none"> 9:15 	Nancy Gillis-Johnson, Pharm.D.; Ph.D. Moffit Cancer Center, Tampa, FL <i>Racial and ethnic differences in clonal hematopoiesis, tumor markers, and outcomes of patients with multiple myeloma</i>
<ul style="list-style-type: none"> 9:30 	Discussion leader: Monica Guzman, Ph.D. Weill Cornell Medicine <i>(45 min call to action-discussion)</i>
10:15 -10:35 am	Coffee Break
10:35- 12:00 pm	<i>Session 6: The burden of lymphoproliferative disorders in Latin America & lower-middle-income countries</i>
<ul style="list-style-type: none"> 10:35 	Carlos Chiattonne, M.D. Faculdade de Ciências Médicas da Santa Casa de São Paulo, Brazil <i>Treatment and outcomes of lymphoma patients in Brazil and LATAM</i>
<ul style="list-style-type: none"> 10:50 	Sai-Juan Chen, M.D. Shanghai Institute of Hematology. <i>The unique landscape of genetic risk factors, treatment and outcomes of leukemia patients in China</i>
<ul style="list-style-type: none"> 11:05 	Robert Baiocchi, M.D. Ohio State University Comprehensive Cancer Center, Columbus, OH <i>EBV+ Lymphomas in Ethiopia</i>

<ul style="list-style-type: none"> • 11:20 • 11:35 	<p>Luis Villela, Ph.D. Universidad Autónoma de Sinaloa, Escuela de Medicina; Hospital General Fernando Ocaranza ISSSTE, Centro Médico Dr. Ignacio Chávez ISSSTESON, Hermosillo, Sonora, Mexico. <i>Real world data of older adults w/ DLBCL- implementation of bispecific antibodies in Mexico</i></p> <p>Discussion leader: Guilherme Duffles Amarante, M.D. Faculdade de Ciências Médicas da Santa Casa de São Paulo, Brazil <i>(25 min call to action-discussion)</i></p>
12:00 pm	Lunch
1:15-1:35 pm	<p><i>Session 7 Project Highlight: The Leukemia & Lymphoma Society's Specialized Center of Research (SCOR) program</i></p> <p>Jean Koff, M.D., M.S. Emory Winship Cancer Institute, Atlanta, GA <i>Translating molecular profiles into treatment approaches to target disparities in lymphoma</i></p>
1:35 – 2:50 pm	<p><i>Session 8: Developing a funding strategy to address disparities</i></p> <ul style="list-style-type: none"> • 1:35 pm Meghan Gutierrez Chief Executive Officer, Lymphoma Research Foundation • 1:45 pm Lore Gruenbaum, Ph.D. Sr. Vice President and Chief Scientific Officer, The Leukemia & Lymphoma Society • 1:55 pm Patricia Frustace Senior Director, Awards & Diversity Programs, American Society of Hematology • 2:05 pm Deirdra R. Terrell, Ph.D. University of Oklahoma Health Sciences Center; ASH MRI Program • 2:15 pm Discussion leader: Christopher Flowers, M.D., M.S., FASCO The University of Texas, MD Anderson Cancer Center <i>(45 min call to action-discussion)</i>
3:00 -3:15 pm	Coffee Break
3:15 – 4:15 pm	<p>Keynote:</p> <p>Kelou Fox, Ph.D. University of California San Diego, San Diego, CA <i>Indigenous data sovereignty and the implementation of benefit-sharing in biomedical research</i></p>
4:15 -4:20 pm	Closing Remarks
4:20 pm	Adjourn